10:45 AM EDT, 07/09/2024 (MT Newswires) -- CalciMedica ( CALC ) said Tuesday the first person has been dosed in its phase 2 trial assessing Auxora to treat severe acute kidney injury with associated acute hypoxemic respiratory failure.

The trial is expected to enroll about 150 people, the company said.

Topline results -- the number of days alive without need for a ventilator or dyalisis -- from the study are expected next year, the company said.

Price: 4.40, Change: +0.15, Percent Change: +3.53